IL-17RA
Use this icon in our BioRender software along with 1000s of others. Create your next scientific figure in minutes!
SIGN UP FREE[{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833383a/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833383a/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333839/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333839/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333838/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333838/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333837/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333837/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333836/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333836/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333835/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333835/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333834/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333834/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333833/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333833/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333832/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333832/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333831/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333831/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333830/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333830/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382f/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382f/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382e/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382e/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382d/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382d/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382c/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382c/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382b/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382b/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833382a/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833382a/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333829/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333829/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333828/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333828/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333827/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333827/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333826/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333826/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333825/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333825/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333824/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333824/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333823/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333823/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333822/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333822/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333821/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333821/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333820/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333820/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381f/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381f/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381e/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381e/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381d/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381d/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381c/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381c/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381b/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381b/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e7002833381a/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e7002833381a/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333819/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333819/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333818/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333818/il-17ra-02.png"},{"image":"https://icons.biorender.com/w75xh75/5fe1fdf676b8e70028333817/il-17ra-02.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5fe1fdf676b8e70028333817/il-17ra-02.png"}]
Keywords
IL-17RA,IL-17RC,Interleukin 17 receptor A,CDw217,CANDF5,CDw217,IL-17R,hIL-17R,IMD51,CTLA-8,glycoprotein,cytokine,proinflammatory,multimeric,FN domain,SEFIR domain,il-17ra